Trade names normally aren’t established and trademarked until after FDA preliminary approval of a drug.  Looks like our friends at Onyx are pretty confident that the FDA will step-up and quickly approve carfilzomib for relapsed/refractory myeloma patients.

Today is a travel day.   The first day of a very busy week.

Concerned about FDA secondary cancer warnings when using Revlimid?

Earlier in the week I promised to write a bit about the exhibit areas you find at ASH and ASCO events.

The risk of developing a secondary cancer following years of ongoing treatment was a red-hot issue one year ago.

As important and exciting as ASH can be, I am always disappointed by how little alternative medicine/supplement data is available.

The two most important myeloma related conferences each year are ASCO and ASH.  ASCO (American Society of Clinical Onclogists) is held every June in Chicago.  It is the largest gathering of oncologists in the world.

A few more quick notes from ASCO before the first of a long running series about ways to improve peripheral neuropathy (PN) starts later today:

Let’s jump right in with more ASCO news.

So much to cover here at ASCO and so little time.  My freelance assignment and book signing are finished.  Time to catch-up on ASCO related multiple myeloma news.

If I have time, I will report on some important myeloma related presentations at the American Society of Clinical Oncology (ASCO) meetings here in Chicago Sunday.  But first, I would like to share a some thoughts about a reception I attended Saturday evening at the Field Museum on Chicago’s lakefront.

Rush, rush, rush this morning, as I get ready to head back to McCormick Place for today’s ASCO meetings.

Before I get started, sounds like I’m not the only one having trouble posting comments lately.  I share the frustration of an old friend of mine:

Lots to cover this morning…

In case you missed it, Saturday the Myeloma Beacon ran a summary of important data released from the International Myeloma Workshop in Paris earlier this month.

Yesterday I jump-started the pre-ASCO announcements about exciting research to be revealed in Chicago in two weeks, focusing on elotuzumab. 

The American Society of Clinical Oncology (ASCO) is the largest cancer related conference in the world. 

Two myeloma related industry press releases went out today. 

The American Society of Clinical Oncology (ASCO) issues an annual report yearly.  Revlimid is prominently mentioned in this years report, published in the Journal of Clinical Oncology, in the “Notable Advances” category.  Here is what the report had to say about Revlimid (lenalidomide):

ASH or ASCO–New Orleans, Chicago or Orlando. Things all work pretty much the same. Find a place to park. Walk miles to get to registration. Wait in line. Walk around looking lost, carrying a big, overstuffed black shoulder bag like everyone else.